Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification

Introduction Genomic profiling provides useful information for diagnosis, treatment, and prognosis, and detection of certain defects, such as DNA repair gene aberrations or microsatellite instability, can possibly lead to optimal treatment, but this testing has not been widely used to inform prostat...

Full description

Bibliographic Details
Main Authors: Tatsuaki Daimon, Takeo Kosaka, Hiroshi Hongo, Eriko Aimono, Kohei Nakamura, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:IJU Case Reports
Subjects:
MDM2
BRCA2
neuroendocrine prostate cancer
genomic profiling
Online Access:https://doi.org/10.1002/iju5.12287

Similar Items

Similar Items